2 Ultra Safe Dividend Stocks to Buy Now
Historically, blue-chip dividend stocks have been good choices for periods…
Sell
46
SAVA Quote, Financials, Valuation and Earnings
Last price:
$2.02
Seasonality move
:
-3.31%
Day range:
$1.96 - $2.04
52-week range:
$1.15 - $42.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.33x
P/B ratio:
0.76x
Volume:
659.4K
Avg. volume:
1.1M
1-year change:
-91.05%
Market cap:
$97.1M
Revenue:
--
EPS (TTM):
-$1.50
Analysts' Opinion
-
Consensus RatingCassava Sciences has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $2.00, Cassava Sciences has an estimated downside of -0.5% from its current price of $2.01.
-
Price Target UpsideAccording to analysts, the highest upside price target is $2.00 representing -100% upside increase from its current price of $2.01.
Fair Value
-
According to the consensus of 1 analyst, Cassava Sciences has -0.5% downside to fair value with a price target of $2.00 per share.
SAVA vs. S&P 500
-
Over the past 5 trading days, Cassava Sciences has underperformed the S&P 500 by -6.94% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Cassava Sciences does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cassava Sciences has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Cassava Sciences reported revenues of --.
Earnings Growth
-
Cassava Sciences has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Cassava Sciences reported earnings per share of -$0.48.
Enterprise value:
-20.2M
EV / Invested capital:
--
Price / LTM sales:
2.33x
EV / EBIT:
--
EV / Revenue:
-0.49x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.19x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$90.2M | -$100.8M | -$146.9M | -$19.9M | -$24.6M | |
| EBITDA | -$88.8M | -$99.3M | -$145.9M | -$19.6M | -$24.4M | |
| Diluted EPS | -$2.04 | -$2.17 | -$1.50 | -$0.43 | -$0.48 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $283.8M | $222.2M | $195M | $134M | $120.2M | |
| Total Assets | $284.1M | $244.2M | $218.1M | $155.7M | $140.9M | |
| Current Liabilities | $2.7M | $6.8M | $13.9M | $77.1M | $13.2M | |
| Total Liabilities | $2.9M | $7.1M | $14.1M | $77.1M | $13.3M | |
| Total Equity | $281.2M | $237.1M | $204M | $78.6M | $127.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$67.2M | -$87.9M | -$109.1M | -$19.1M | -$11.3M | |
| Cash From Investing | -$2.6M | -$57K | -$103K | -- | -- | |
| Cash From Financing | $47.7M | $24.7M | $102.4M | $22.2M | $90K | |
| Free Cash Flow | -$69.9M | -$88M | -$109.1M | -$19.1M | -$11.3M | |
SAVA
Sector
Market Cap
$97.1M
$33.4M
Price % of 52-Week High
4.76%
45.25%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.66%
1-Year Price Total Return
-91.05%
-40%
Beta (5-Year)
-2.309
0.653
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.10
200-day SMA
Sell
Level
$11.79
Bollinger Bands (100)
Sell
Level
1.63 - 2.69
Chaikin Money Flow
Sell
Level
-106.6M
20-day SMA
Buy
Level
$1.92
Relative Strength Index (RSI14)
Buy
Level
55.79
ADX Line
Buy
Level
33.37
Williams %R
Neutral
Level
-57.0093
50-day SMA
Buy
Level
$1.73
MACD (12, 26)
Buy
Level
0.10
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Neutral
Level
433.5M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer’s disease dementia. It has one business segment: the development of novel drugs and diagnostics.
Stock Forecast FAQ
In the current month, SAVA has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The SAVA average analyst price target in the past 3 months is $2.00.
-
Where Will Cassava Sciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cassava Sciences share price will drop to $2.00 per share over the next 12 months.
-
What Do Analysts Say About Cassava Sciences?
Analysts are divided on their view about Cassava Sciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cassava Sciences is a Sell and believe this share price will rise from its current level to $2.00.
-
What Is Cassava Sciences's Price Target?
The price target for Cassava Sciences over the next 1-year time period is forecast to be $2.00 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is SAVA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cassava Sciences is a Hold. 1 of 1 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of SAVA?
You can purchase shares of Cassava Sciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cassava Sciences shares.
-
What Is The Cassava Sciences Share Price Today?
Cassava Sciences was last trading at $2.02 per share. This represents the most recent stock quote for Cassava Sciences. Yesterday, Cassava Sciences closed at $2.01 per share.
-
How To Buy Cassava Sciences Stock Online?
In order to purchase Cassava Sciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Asana Stock Be in 5 Years?
Asana stock hasn’t given many investors on Wall Street any…
Where Will Dell Stock Be in 5 Years?
So you’re looking at Dell (NASDAQ: DELL) and wondering, “Is…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
31
REGN alert for May 31
Regeneron Pharmaceuticals [REGN] is down 19.04% over the past day.
Buy
55
RGC alert for May 31
Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.
Sell
42
AMBA alert for May 31
Ambarella [AMBA] is down 15.13% over the past day.
